Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model
Yu‐Xiong Feng, Tao Wang, Yue‐Zhen Deng, Pengyuan Yang, Jing‐Jing Li, Dong‐Xian Guan, Fan Yao, Yin‐Qiu Zhu, Ying Qin, Hui Wang, Nan Li, Meng‐Chao Wu, Hong‐Yang Wang, Xiao‐Fan Wang, Shu‐Qun Cheng, Dong Xie – 12 November 2010 – Surgical resection is the first‐line treatment for hepatocellular carcinoma (HCC) patients with well‐preserved liver function. Nevertheless, the rate of postoperative recurrence at 5 years is as high as 70%, and this gravely jeopardizes the therapeutic outcome. Clearly, new approaches are needed for preventing the relapse of this deadly disease.